menu
    • menu
    [{"orgOrder":0,"company":"Crown Laboratories","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Crown Laboratories","amount2":0.92000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"","sponsorNew":"Crown Laboratories \/ Crown Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Crown Laboratories \/ Crown Laboratories"},{"orgOrder":0,"company":"Crown Laboratories","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Crown Laboratories","amount2":0.92000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Intramuscular Injection","sponsorNew":"Crown Laboratories \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Crown Laboratories \/ Crown Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals by Crown Laboratories

    Menu

    Crown Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crown Laboratories

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Crown Laboratories

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Revance Therapeutics

                            Deal Size : $924.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Crown Laboratories Completes Acquisition of Revance Therapeutics

                            Details : The combined company's flagship brands will include DAXXIFY (daxibotulinumtoxinA-lanm), an acetylcholine release inhibitor and neuromuscular blocking agent.

                            Product Name : Daxxify

                            Product Type : Protein

                            Upfront Cash : $924.0 million

                            February 07, 2025

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Revance Therapeutics

                            Deal Size : $924.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Crown Laboratories

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Crown Laboratories

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Revance Therapeutics

                            Deal Size : $924.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Crown Laboratories and Revance Announce Entry into Merger Agreement

                            Details : Combined company's flagship brands will include DAXXIFY (daxibotulinumtoxinA-lanm), an acetylcholine release inhibitor and neuromuscular blocking agent.

                            Product Name : Daxxify

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Revance Therapeutics

                            Deal Size : $924.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth